Source:http://linkedlifedata.com/resource/pubmed/id/16425263
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
2006-4-3
|
pubmed:abstractText |
Tumor progression and recurrence of cervical cancer is associated with upregulation of matrix metalloproteinase 2 (MMP-2). We evaluated the location, origin and activity of MMP-2 in cervical squamous cell carcinomas in comparison with MT1-MMP (MMP-14), TIMP-2 and extracellular matrix metalloproteinase inducer (EMMPRIN). Positive immunostaining for MMP-2 in malignant cells was detected in 83% of the patients. Two patterns of tumor cell MMP-2 staining were observed: either homogenous in all tumor cells or confined to the cells neighboring the stroma (tumor-border staining pattern, TBS). Fluorescence in situ zymography showed active MMP-2 mainly around tumor nodules displaying TBS. The MMP-2 staining of TBS tumors correlated significantly with the presence of TIMP-2 and MT1-MMP, proteins involved in docking MMP-2 to the cell surface and essential for MMP-2 activation. In situ mRNA hybridization in TBS tumors demonstrated more abundant presence of MMP-2 mRNA in neighboring myofibroblasts than in the adjacent tumor cells. Moreover, the TBS MMP-2 pattern correlated with the presence of EMMPRIN (p = 0.023), suggesting that tumor cells induce MMP-2 production in nearby stromal cells. This pro-MMP-2 could subsequently be activated on tumor cells via the presence of MT1-MMP and TIMP-2. The biological relevance of this locally activated MMP-2 was underscored by the observation that only the TBS pattern of MMP-2 significantly correlated with decreased survival. In conclusion, the colocalization of EMMPRIN, MT1-MMP and TIMP-2 in human cervical carcinomas seems to be involved in a specific distribution pattern of tumor cell bound MMP-2, which is related with local proteolytic activity and therefore might be associated with worse prognosis of the patients.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD147,
http://linkedlifedata.com/resource/pubmed/chemical/BSG protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Matrix Metalloproteinase 2,
http://linkedlifedata.com/resource/pubmed/chemical/Matrix Metalloproteinases,
http://linkedlifedata.com/resource/pubmed/chemical/Matrix Metalloproteinases...,
http://linkedlifedata.com/resource/pubmed/chemical/Tissue Inhibitor of...
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0020-7136
|
pubmed:author |
pubmed-author:DreefEnno JEJ,
pubmed-author:FleurenGert JanGJ,
pubmed-author:GorterArkoA,
pubmed-author:HanemaaijerRoelandR,
pubmed-author:KenterGemma GGG,
pubmed-author:Mulder-StapelAdri AAA,
pubmed-author:PrinsFrans AFA,
pubmed-author:SierCornelis F MCF,
pubmed-author:ZijlmansHenry J M A AHJ,
pubmed-author:ZuidwijkKimK
|
pubmed:copyrightInfo |
Copyright 2006 Wiley-Liss, Inc.
|
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
118
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2991-8
|
pubmed:dateRevised |
2007-7-24
|
pubmed:meshHeading |
pubmed-meshheading:16425263-Antigens, CD147,
pubmed-meshheading:16425263-Carcinoma, Squamous Cell,
pubmed-meshheading:16425263-Enzyme Activation,
pubmed-meshheading:16425263-Female,
pubmed-meshheading:16425263-Fluorescent Antibody Technique,
pubmed-meshheading:16425263-Humans,
pubmed-meshheading:16425263-Immunohistochemistry,
pubmed-meshheading:16425263-In Situ Hybridization,
pubmed-meshheading:16425263-Matrix Metalloproteinase 2,
pubmed-meshheading:16425263-Matrix Metalloproteinases,
pubmed-meshheading:16425263-Matrix Metalloproteinases, Membrane-Associated,
pubmed-meshheading:16425263-Prognosis,
pubmed-meshheading:16425263-Tissue Inhibitor of Metalloproteinase-2,
pubmed-meshheading:16425263-Uterine Cervical Neoplasms
|
pubmed:year |
2006
|
pubmed:articleTitle |
EMMPRIN-induced MMP-2 activation cascade in human cervical squamous cell carcinoma.
|
pubmed:affiliation |
Department of Pathology, Leiden University Medical Center, The Netherlands. C.F.M.Sier@lumc.nl
|
pubmed:publicationType |
Journal Article
|